AMERICAN COLLEGE OF RHEUMATOLOGY Research NewsSHARE PRINT E-MAIL ATLANTA — New research presented at ACR Convergence, the American College Rheumatology’s annual meeting, reveals that romosozumab, an osteoporosis drug, produces substantial gains in bone mineral density in the hip and lumbar spine within one year, and that transitioning patients to a potent antiresorptive drug can lead to even...
Tag: <span>Romosozumab</span>
Post
Romosozumab added to guideline for management of osteoporosis
(HealthDay)—In an Endocrine Society guideline update, published online in the March issue of the Journal of Clinical Endocrinology & Metabolism, recommendations are presented for the use of romosozumab in the pharmacological management of osteoporosis in postmenopausal women. Dolores Shoback, M.D., from the San Francisco Veterans Affairs Medical Center, and colleagues updated guidelines for the pharmacologic...